BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35835439)

  • 1. A simulator with realistic and challenging scenarios for virtual T1D patients undergoing CSII and MDI therapy.
    Estremera E; Cabrera A; Beneyto A; Vehi J
    J Biomed Inform; 2022 Aug; 132():104141. PubMed ID: 35835439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.
    Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
    IEEE Trans Biomed Eng; 2019 Oct; 66(10):2889-2896. PubMed ID: 30735983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Nutr Metab; 2004 Apr; 17(2):84-9. PubMed ID: 15244099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
    Pickup JC; Kidd J; Burmiston S; Yemane N
    Diabetes Metab Res Rev; 2006; 22(3):232-7. PubMed ID: 16389648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial.
    Dicembrini I; Pala L; Caliri M; Minardi S; Cosentino C; Monami M; Mannucci E
    Diabetes Obes Metab; 2020 Aug; 22(8):1286-1291. PubMed ID: 32166907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes.
    Zhang L; Leng X; Tian F; Xiao D; Xuan J; Yang H; Liu J; Chen Z
    Postgrad Med; 2022 Aug; 134(6):627-634. PubMed ID: 35695267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes.
    Alemzadeh R; Palma-Sisto P; Parton EA; Holzum MK
    Diabetes Technol Ther; 2005 Aug; 7(4):587-96. PubMed ID: 16120030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
    Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
    Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures.
    Thomas MG; Avari P; Godsland IF; Lett AM; Reddy M; Oliver N
    Diabetes Obes Metab; 2021 Nov; 23(11):2521-2528. PubMed ID: 34286892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
    Grunberger G; Bhargava A; Ly T; Zisser H; Ilag LL; Malone J; Fan L; Zhang S; Johnson J
    Diabetes Obes Metab; 2020 Mar; 22(3):434-441. PubMed ID: 31865633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.